Journey Medical Corp reports results for the quarter ended June 30 - Earnings Summary

• Journey Medical Corp DERM.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -17 cents. The mean expectation of four analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -16 cents to -6 cents per share.

• Revenue rose 1% to $15.01 million from a year ago; analysts expected $14.93 million.

• Journey Medical Corp's reported EPS for the quarter was a loss of 16 cents​.

• The company reported a quarterly loss of $3.8 million.

• Journey Medical Corp shares had risen by 9.6% this quarter and gained 101.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 6.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Journey Medical Corp is $10.00, about 21.3% above its last closing price of $7.87

This summary was machine generated from LSEG data August 12 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)